Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016 Yot TeerawattananonAlia Luz Editorial 11 December 2015 Pages: 1 - 3
The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System? James F. O’MahonyDiarmuid Coughlan Current Opinion 26 October 2015 Pages: 5 - 11
Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers Elamin H. ElbashaJagpreet Chhatwal Practical Application 07 December 2015 Pages: 13 - 22
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene Hedwig M. BlommesteinNigel ArmstrongMaiwenn J. Al Review Article Open access 28 August 2015 Pages: 23 - 31
The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial David M. MeadsAndrea MarshallHugo E. R. Ford Original Research Article 04 September 2015 Pages: 33 - 42
Cost-of-Illness Studies: An Updated Review of Current Methods Eberechukwu OnukwughaJacquelyn McRaeC. Daniel Mullins Original Research Article 18 September 2015 Pages: 43 - 58
Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries EUnetHTA Joint Action 2, Work Package 7, Subgroup 3Emelie HeintzThomas Davidson Original Research Article 07 October 2015 Pages: 59 - 76
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada William HerringIsobel PearsonKavisha Jayasundara Original Research Article 30 October 2015 Pages: 77 - 90